SARS-CoV-2 hyperimmune globulin for severely immunocompromised patients with COVID-19: a randomised, controlled, double-blind, phase 3 trial
Sammy Huygens, Quincy Hofsink, Inger S Nijhof, Abraham Goorhuis, Arnon P Kater, Peter AW te Boekhorst, Francis Swaneveld, Věra MJ Novotný, Susanne Bogers, Matthijs RA Welkers, Grigorios Papageorgiou, Bart J Rijnders, Jarom Heijmans
doi: https://doi.org/10.1101/2022.04.04.22273314
